Formats
  1. Journal Article (66747)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (661)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39034)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22057)
  4. Surgery (21249)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15763)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5599)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115372)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia from the PACE and OPTIC trials
    Meeting Abstract

    Apperley, J.; Kantarjian, H.; Deininger, M.; Abruzzese, E.; Cortes, J.; Chuah, C.; DeAngelo, D. J.; DiPersio, J.; Hochhaus, A.; Lipton, J. H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • BRUIN CLL-322: A phase 3 open-label, randomized study of fixed-duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress)
    Meeting Abstract

    Wierda, W. G.; Pagel, J. M.; Davids, M. S.; Zinzani, P. L.; Lu, Y.; Liu, H.; Shahda, S.; Leow, C. C.; Tam, C. S.; Woyach, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor-pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (Trial in progress)
    Meeting Abstract

    Hill, M.; Sharman, J. P.; Jurczak, W.; Coombs, C. C.; Wang, D.; Ku, N. C.; Guntur, A.; Shahda, S.; Leow, C. C.; Ghia, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Coombs, C. C.; Pagel, J. M.; Shah, N. N.; Lamanna, N.; Munir, T.; Lech-Maranda, E.; Eyre, T. A.; Woyach, J. A.; Wierda, W. G.; Cheah, C. Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib or conventional care regimens (CCR) in the randomized, open-label, phase 3 IDHENTIFY trial
    Meeting Abstract

    DiNardo, C. D.; de Botton, S.; Risueño, A.; Schuh, A. C.; Lowenberg, B.; Kim, H. J.; Vyas, P.; Wei, A. H.; Stein, E. M.; Döhner, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • SELECT-AML-1 trial in progress: A phase 2 study of tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy
    Meeting Abstract

    Kambhampati, S.; Eghtedar, A.; McMahon, C.; de Botton, S.; Pigneux, A.; Ball, B.; Borthakur, G.; Angela, V.; Gausman, J. A.; Baker, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • First results of a phase II study (STIMULUS-AML1) investigating sabatolimab plus azacitidine plus venetoclax in patients with newly diagnosed acute myeloid leukemia (ND AML)
    Meeting Abstract

    Zeidan, A. M.; Westermann, J.; Kovacsovics, T.; Assouline, S.; Schuh, A. C.; Kim, H. J.; Macias, G. R.; Sanford, D.; Luskin, M. R.; Stein, E. M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Trial in progress: Phase Ib/II study of siremadlin in combination with venetoclax plus azacitidine in patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy (IC)
    Meeting Abstract

    Daver, N. G.; Wei, A. H.; Stein, E. M.; DeAngelo, D. J.; Pathak, D.; Xu, Y. N.; Grzesiak, S.; Venditti, A.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Outcomes based on sequential use of venetoclax based therapy and targeted therapy in acute myeloid leukemia (AML)
    Meeting Abstract

    Stahl, M.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Adjusted comparison of teclistamab versus physician's choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma
    Meeting Abstract

    Mateos, M. V.; Chari, A.; Usmani, S.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save